quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 24, 2026

CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy?

View original at finance.yahoo.com
CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy? Behind every generative AI model and autonomous system is massive compute infrastructure, especially data centers full of GPUs that train and serve models…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Management remains confident in its ability to meet long-term demand, scale capacity and strengthen its position in AI cloud as new offerings, partnerships and federal deals ramp

    80% confidence
  • Spending on AI data centers and accelerated computing is surging, creating a multitrillion-dollar opportunity

    80% confidence
  • MSFT remains the stronger long-term buy, with AI monetization through Azure and Copilot, massive RPO visibility and diversified cash flows

    80% confidence
  • CRWV looks better positioned for near-term outperformance because we are in the AI capacity-deployment phase

    80% confidence
  • Active power is expected to exceed 850 MW by year-end

    80% confidence
  • The Core Scientific acquisition decision does not affect its growth outlook

    80% confidence
  • Management remains upbeat about ongoing growth across commercial and enterprise segments, driven by global capacity buildout and multiple revenue pillars

    80% confidence
  • In terms of valuation, CRWV seems to be a better pick at the moment

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy? — Source | Via News | pt.VIA.NEWS